EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances

Mikel Portu iD, Mario Balsa iD, Maria Cotaina, Georgia Anguera iD, Xavier García Del Muro, Ferran Algaba, Pablo Maroto

Cancers · 16.03.2026 · 18 (6) · 958

DOI: 10.3390/cancers18060958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.03.2026. Verfasst von Mikel Portu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinomas (RCCs) driven by TFE3 rearrangement or TFEB alteration (MiT-RCC) account for up to 40% of pediatric RCCs but are rare in adults. MiT-RCC includes fusion-driven tumors with TFE3 or TFEB rearrangements (translocation RCC, tRCC) and TFEB-amplified RCC. Morphologic heterogeneity and historical exclusion from trials have limited evidence-based management. We reviewed the literature through January 2026 to summarize molecular biology, pathology, clinical behavior, and systemic therapy. MiT-RCC comprises biologically distinct entities: TFEB-rearranged tumors are often indolent in younger patients, whereas TFEB-amplified RCC, frequently co-amplifying VEGFA, behaves aggressively in older adults. In TFE3-rearranged RCC, fusion partner influences prognosis. Paradoxically, ASPSCR1::TFE3 fusions have the poorest natural history, yet fusion-annotated cohorts suggest these tumors may derive particular benefit from immune checkpoint inhibitor (ICI) plus VEGF receptor tyrosine kinase inhibitor (VEGFR-TKI) combinations. Diagnostic advances including GPNMB immunohistochemistry, TRIM63 RNA in situ hybridization, and sequencing-based fusion panels improve detection of cryptic alterations. First-line ICI + VEGFR-TKI combinations are increasingly favored for metastatic tRCC in eligible patients, while optimal management of TFEB-amplified RCC remains uncertain.

Schlagwörter

Stichwörter der Autor:innen

MiT-RCCTFE3TFEBgene fusionimmune checkpoint inhibitorprecision oncologytranslocation renal cell carcinomatyrosine kinase inhibitor

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Medical Oncology Department, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain.
  • Pathology Department, Fundació Puigvert, 08025 Barcelona, Spain.

ORCID-Profile: Mikel Portu, Mario Balsa, Georgia Anguera

Zitieren

APA

Portu, M., Balsa, M., Cotaina, M., Anguera, G., García Del Muro, X., Algaba, F., & Maroto, P. (2026). TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Cancers, 18(6), 958. https://doi.org/10.3390/cancers18060958

Vancouver

Portu M, Balsa M, Cotaina M, Anguera G, García Del Muro X, Algaba F, et al. TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances. Cancers. 2026;18(6):958. doi:10.3390/cancers18060958

BibTeX
@article{Portu2026,
  author = {Portu, Mikel and Balsa, Mario and Cotaina, Maria and Anguera, Georgia and García Del Muro, Xavier and Algaba, Ferran and Maroto, Pablo},
  title = {TFE3-Rearranged and TFEB-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {958},
  doi = {10.3390/cancers18060958}
}
Kostenlos starten →